Tampa, Florida 2021-02-23 11:26:43 –
Washington (AP) —The top developers of the COVID-19 vaccine in the United States are set to face congressional questions about the limited supply of shots needed to end the pandemic.
Prior to the hearing, Johnson & Johnson announced that the initial supply of one-shot vaccine would be limited to 20 million by the end of March. J & J Will tell Congressmen face “significant challenges” in expanding production.
Although the pace of vaccination is increasing nationwide, the demand for shots continues to exceed the limited supply distributed by the US government.
A committee of the Energy Commerce Committee asks executives of five companies what they can do to boost manufacturing. In front of the legislators are representatives of Pfizer, Moderna, J & J, AstraZeneca and Nova Bucks.
“Currently, the most pressing issue is the lack of vaccine doses,” Diana Degette said at a hearing. “Some of the companies here today are still short of the number of doses they promised to offer first when they last testified before this subcommittee in July.”
Degette said Tuesday’s hearing was a “direct assessment” of the manufacturing process.
J&J announces 20M vaccine doses available by March as drugmakers face questions on Capitol Hill Source link J&J announces 20M vaccine doses available by March as drugmakers face questions on Capitol Hill